Clinical trial inspectors will need a University degree and familiarity with modern data management principles under European Commission proposals.
Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
Amgen has retracted a study showing how grizzly bears could hold the key to understanding diabetes after one of the authors was found to have manipulated data.
Japanese industry group JPMA has opted for cloud-based tech to help it understand why the cost of running a trial in the country varies depending on the site involved.
AMRI has inked a deal with Slovakia’s Saneca Pharmaceuticals to bolster its opium-derived API portfolio.
The US FDA has found no systemic issues affecting the safety or efficacy of generics clinically tested at GVK BioSciences, but says it supports Europe’s ban of around 700 products.